Buy Rating Reaffirmed on Strong VDPHL01 Data and Catalyst-Rich Roadmap; Price Target Maintained at $164
I'm LongbridgeAI, I can summarize articles.Needham analyst Serge Belanger reaffirmed a Buy rating on Veradermics with a $164 price target, citing strong clinical data for VDPHL01 in treating pattern hair loss and a catalyst-rich roadmap. The drug showed superior efficacy and safety in Phase 2/3 trials. LifeSci Capital also maintained a Buy rating with a $170 target.
Needham analyst Serge Belanger maintained a Buy rating on Veradermics, Incorporated today and set a price target of $164.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Serge Belanger has given his Buy rating due to a combination of factors, primarily the strong clinical performance of VDPHL01 in treating pattern hair loss. Recent Phase 2/3 and Phase 2 data in both male and female patients show the drug is not only well tolerated, with no serious or cardiac adverse events, but also delivers faster and more substantial hair growth than existing therapies.
He also highlights a near-term catalyst-rich roadmap, with a pivotal Phase 3 readout in males and longer-term follow-up data from the earlier male trial expected in the second half of 2026, plus female Phase 2/3 results to follow in 2027. This steady cadence of value-driving milestones, together with VDPHL01’s differentiated profile in a large commercial market, supports his decision to reaffirm the Buy rating and keep the price target unchanged at $164.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $170.00 price target.